Lilly Tirzepatide Explained: the Facts Behind the Medicine

The biggest misconception: tirzepatide and semaglutide do the same thing

Most people who arrive at this search already know tirzepatide is a GLP-1 medicine. What surprises them is finding out it does something additional. Semaglutide (the active ingredient in Wegovy) targets GLP-1 receptors only. Tirzepatide targets both GLP-1 and GIP receptors, which is why clinicians and researchers describe it as a dual agonist. GIP (glucose-dependent insulinotropic polypeptide) is a gut hormone that plays its own role in how the body stores fat and regulates appetite. By activating both pathways, Lilly's tirzepatide, developed and marketed under the Eli Lilly Mounjaro brand, produces a physiological response that is distinct from a single-pathway medicine, not just a stronger version of the same thing.

In practical terms, both medicines slow gastric emptying, reduce appetite and improve blood-sugar regulation. But the dual mechanism is why SURMOUNT-1 (one of the largest weight-management trials conducted to date, involving 2,539 adults) reported average reductions of around 20–21% of body weight at the 15 mg dose over 72 weeks. The head-to-head SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, found tirzepatide produced greater average weight reduction than semaglutide 2.4 mg over the same period. That comparison matters, but which medicine suits a particular person is a clinical decision, not a league-table choice. You can explore the fuller picture of how tirzepatide works and what it treats in more detail.

The Mounjaro UK overview covers the pen format, the available strengths and the titration schedule if you want a practical rather than a mechanistic focus.

What Eli Lilly actually studied, and what the evidence tells UK patients

Lilly's SURMOUNT programme ran across thousands of adults with obesity, with and without type 2 diabetes, across multiple countries including UK sites. SURMOUNT-1 specifically enrolled adults without diabetes and reported those headline weight-loss figures at 15 mg. NICE reviewed that evidence when appraising tirzepatide in late 2024, recommending it for NHS use in adults with a BMI of 35 or above alongside at least one weight-related condition, with thresholds set 2.5 kg/m² lower for some ethnic backgrounds under UK clinical guidance. NICE's appraisal of tirzepatide (TA1026) sets out the full recommendation, including what happens if less than 5% of body weight is lost after six months at the highest tolerated dose.

For private treatment, licensed eligibility is broader: adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition such as hypertension, high cholesterol, obstructive sleep apnoea or prediabetes. A prescriber considers the whole picture, not just a BMI number. Those curious about how tirzepatide has performed commercially since Lilly launched it will find the growth figures striking, demand across European markets has risen sharply, which is part of why supply and pricing have both shifted since 2025.

Treatment starts at 2.5 mg, a dose whose job is to let the body adjust, not to produce weight loss immediately. It is titrated upward, typically in four-week steps, by the prescriber based on tolerability and response. Exact timing and adjustments always follow the prescriber's guidance and the Patient Information Leaflet, not a general schedule read online.

Side effects that come up most often, and when to get medical help

The side-effect profile for Lilly's tirzepatide is well characterised from the SURMOUNT trial programme and from post-authorisation monitoring. Most are gastrointestinal: nausea, loose stools, constipation, indigestion and burping are the most frequently reported. They tend to be most noticeable in the first week or two after a dose starts or increases, then settle. Fatigue, headache and mild dizziness appear less commonly. Injection-site reactions (redness or tenderness at the abdomen, thigh or upper arm) are generally minor. The NHS tirzepatide medicines page lists the full side-effect categories with clear guidance on severity.

Two situations require prompt medical attention. Severe, persistent stomach pain that radiates toward the back (with or without vomiting) needs urgent assessment; it may indicate acute pancreatitis, which the MHRA highlighted in a Drug Safety Update in January 2026 as an infrequent but serious risk with GLP-1 medicines. Suspected allergic reactions (facial swelling, difficulty breathing, rapid heart rate) also require emergency help. Women taking oral contraceptives should be aware that tirzepatide may reduce pill absorption; a non-oral method of contraception is recommended for the first four weeks of treatment and for four weeks after each dose increase. Patients who have questions about legal action relating to the medicine can read about the Eli Lilly lawsuit tirzepatide claims and what they cover before raising concerns with their prescriber. Anyone who wants to raise a concern about a side effect can report it directly at the MHRA's Yellow Card scheme.

Tirzepatide is not recommended during pregnancy, breastfeeding or when trying to conceive, and it is not licensed for under-18s. A prescriber reviews all of this at the consultation stage. You can find our clinical team's approach explained on our clinical team profile.

Getting tirzepatide in the UK: NHS routes, private routes and what to watch for

NHS access to tirzepatide is phased. From June 2025, adults with a BMI of 40 or above alongside four or more qualifying conditions became eligible; the cohort for BMI 35–39.9 activated in June 2026. Even within eligible groups, provision is through specialist services and depends on local commissioning, so waiting times vary. Private prescription is the route many people take when they don't meet NHS criteria yet, or when a shorter timeline matters, payday in January, a health goal tied to a specific month, a holiday fast approaching.

Any private route must go through a regulated UK pharmacy. The GPhC's online register lets you check any pharmacy's registration before you share personal or medical information. Counterfeit pens have been seized in significant quantities across the UK; the MHRA has warned that pens sold through social media or by sellers with no visible registration, and supplied without a prescription, are a serious safety risk. Genuine supply means Eli Lilly's UK-authorised stock, dispensed by a GPhC-registered pharmacy following a clinical assessment.

If you're considering buying Mounjaro through an online pharmacy, the steps to verify the pharmacy are straightforward and worth taking. Our own GPhC registration is publicly verifiable at the pharmacy register (number 9012878). The broader context of weight-loss treatment options is worth reading alongside this page if you're still at the comparison stage. When you're ready to find out whether tirzepatide is clinically suitable for you, the place to begin is a free consultation with our prescribers.